Mirae Asset Global ETFs Holdings
INZY

Mirae Asset Global ETFs Holdings’s Inozyme Pharma INZY Stock Holding History

Mirae Asset Global ETFs Holdings’s Portfolio INZY Stock Details INZY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-30,982
Closed -$28.2K – 3119
2025
Q1 		$28.2K Buy
30,982
+1,326
+4% +$1.84K ﹤0.01% 2939
2024
Q4 		$82.1K Buy
29,656
+1,292
+5% +$4.91K ﹤0.01% 2783
2024
Q3 		$148K Buy
28,364
+3,959
+16% +$20.6K ﹤0.01% 2520
2024
Q2 		$109K Buy
+24,405
New +$118K ﹤0.01% 2528

Other funds holding INZY

BCM
Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.54B AUM 41.83% 1-Year Est. Return
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return

Mirae Asset Global ETFs Holdings's INZY Position: Q2 2025 in Review

Mirae Asset Global ETFs Holdings sold out of Inozyme Pharma (INZY) in Q2 2025, closing a stake of 30,982 shares — an estimated $28.2K sold.

Mirae Asset Global ETFs Holdings first reported a position in INZY in Q2 2024 and held it in 4 quarters. The position peaked at $148K in Q3 2024. 86 funds tracked by Wall St. Rank hold INZY as of Q2 2025.

  • Mirae Asset Global ETFs Holdings reported no remaining Inozyme Pharma position as of Q2 2025 after selling out during the quarter.
  • Mirae Asset Global ETFs Holdings sold 30,982 Inozyme Pharma shares in Q2 2025, an estimated $28.2K.
  • Mirae Asset Global ETFs Holdings first reported a position in Inozyme Pharma in Q2 2024 and held it in 4 quarters.
  • Mirae Asset Global ETFs Holdings's Inozyme Pharma position peaked at $148K in Q3 2024.
  • 86 funds tracked by Wall St. Rank held Inozyme Pharma as of Q2 2025.

Based on Mirae Asset Global ETFs Holdings's 13F filing for Q2 2025, filed 14 Aug 2025.